WO2025137611A1

WO2025137611A1 - Cannabinoid compositions for treatment of post-traumatic epilepsy

Info

Publication number: WO2025137611A1
Application number: PCT/US2024/061522
Authority: WO
Inventors: Michael Hunter LAND; Brian Kent BRANDLEY; George Bennett HODGIN; Lucas J. ZUMSTEIN; Justyna KULPA
Original assignee: Biopharmaceutical Research Co
Current assignee: Biopharmaceutical Research Co
Priority date: 2023-12-22
Filing date: 2024-12-20
Publication date: 2025-06-26
Anticipated expiration: 2026-06-22

Abstract

Cannabinoid compositions formulated for use in the treatment of post-traumatic epilepsy (PTE) are disclosed. The compositions include cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC) as the major components therein, which may be isolated, purified or extracted from cultivars and blended together. The compositions include CBD, CBG and THC in certain ratios, formulated for the use in the treatment of PTE.

Description

776772000640 CANNABINOID COMPOSITIONS FOR TREATMENT OF POST-TRAUMATIC EPILEPSY CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority to U.S. Provisional Patent Application Nos. 63/614,441, filed December 22, 2023, and 63/638,863, filed April 25, 2024, each of which is incorporated herein by reference in their entirety. FIELD [0002] The present disclosure relates generally to treatment of post-traumatic epilepsy (PTE), and more specifically to the use of certain cannabinoid compositions for treating PTE. BACKGROUND [0003] Post-traumatic epilepsy (PTE) is a debilitating condition characterized by recurrent seizures that develop as a result of a traumatic brain injury (TBI). Estimates suggest that approximately 30% to 50% of patients with PTE may have refractory epilepsy, where seizures persist despite treatment with multiple antiseizure medications (ASMs) and other therapeutic interventions. Additionally, debilitating side effects of medications often impact treatment compliance and quality of life. For this reason, the search for alternative treatments that can offer improved outcomes and quality of life for these patients is of great importance. Thus, what is needed in the art are alternative treatments for PTE. BRIEF SUMMARY [0004] In some aspects, provided is a method of treating post-traumatic epilepsy (PTE) in a human in need thereof. In some embodiments, the method comprises: administering a cannabinoid composition comprising cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC) present as a major component therein. [0005] In certain embodiments, the CBD, CBG and/or THC may be provided as: (i) one or more botanical drug substances (“BDS”); (ii) one or more extracts from cannabis plants (“extracts”); (iii) one or more extracts from cannabis plants blended with additional sources of CBD, CBG and/or THC (“blended extracts”); (iv) purified CBD, CBG and/or THC, e.g., obtained from purifying the extracts or blended extracts; or (v) isolates of CBD, CBG and/or THC. In some variations, the cannabinoid composition further comprises other cannabinoids 1 ^sf-6205389 776772000640 and non-cannabinoids (e.g., terpenes) formulated in a vehicle (e.g., a lipid vehicle) to yield the final product composition that may be administered to a human in need thereof. Such other cannabinoids and non-cannabinoids (e.g., terpenes) are present from the source from which the composition is obtained. DETAILED DESCRIPTION [0006] The following description sets forth exemplary compositions, methods, parameters and the like. It should be recognized, however, that such description is not intended as a limitation on the scope of the present disclosure but is instead provided as a description of exemplary embodiments. [0007] Cannabinoids are compounds structurally or pharmacologically related to the constituents of the cannabis plant or to the endogenous agonists (endocannabinoids) of the cannabinoid receptors CB1 or CB2. Cannabinoids may be naturally derived from cannabis plants or synthetically derived. Cannabis plants comprise a highly complex mixture of compounds, and hundreds of such compounds have been identified. [0008] Traditionally, crude extracts from cannabis plants containing CBD have been used by patients suffering from various diseases and disorders. However, such crude products are generally unsuitable for use in pharmaceutical formulations. Those seeking to prepare more consistent CBD formulations for use in treating diseases or disorders have made an effort to either prepare CBD synthetically or attempt to remove all compounds other than CBD, particularly psychoactive compounds such as THC, from plant derived cannabinoids. [0009] The present invention encompasses the surprising discovery that particular compositions comprising CBD in combination with CBG and THC have an improved therapeutic efficacy for treating seizures in post-traumatic epilepsy (PTE). Cannabinoid Compositions [0010] In some aspects, provided are cannabinoid compositions comprising a combination of CBD, CBG and THC, which are collectively present as the major components of the cannabinoids in the compositions. In certain embodiments, the compositions herein, including the compositions administered in the methods herein, are drug formulations that comprise a combination of extracts or isolated compounds from one or more cultivars that are blended to achieve certain ratios of CBD, CBG and THC. For example, in some variations, 2 ^sf-6205389 776772000640 extracts from genetically identical clones of three different cultivars (e.g., high CBD cultivars, high CBG cultivars, and high THC cultivars) may be used to produce the drug formulations. The components of the cannabinoid compositions provided herein are described in further detail below. [0011] In some variations, the CBD, CBG and THC are collectively greater than 50%, greater than 60%, greater than 70%, greater 80%, greater than 85%, greater than 90%, greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 9%; or between 50% and 99.9%, between 60% and 99%, between 70% and 99%, between 80% and 99%, between 85% and 99%, between 85% and 95%, or between 90% and 99% by weight of the cannabinoids present in the composition. [0012] It should be understood that in addition to the cannabinoids, in some embodiments, the cannabinoid compositions may include other cannabinoids as well as non- cannabinoids formulated in a vehicle, such as a lipid vehicle, as described in further detail below. Such other cannabinoids as well as non-cannabinoids are present from the cannabis plant from which the compositions are obtained. Thus, in some variations, the composition comprises CBD, CBG and THC in the ratios and amounts as described herein, as well as other components, such as terpenes, and lipid excipients. [0013] The structures of CBD, CBG and THC are well understood in the art. In some embodiments, the THC present in the compositions herein is primarily in the form of (–)- delta-9-trans-tetrahydrocannabinol (Δ9-THC). [0014] In some variations, the CBD, CBG and THC are present in a molar ratio between about 100:100:1 and about 1:1:1; or between about 100:50:1 and about 20:1:1. In certain variations, the CBD and CBG are present in a molar ratio between about 100:1 and about 1:1. In certain variations, the molar ratio of CBD and THC is between about 50:1 and about 1:1. [0015] In some variations, the CBD, CBG and THC are present in a weight ratio between about 100:100:1 and about 1:1:1; or between about 100:50:1 and about 20:1:1. In some variations, the CBD, CBG and THC are present in a weight ratio between about 1:0.016- 0.15:0.003-0.03. In certain variations, the CBD and CBG are present in a weight ratio between about 100:1 and about 1:1. In certain variations, the weight ratio of CBD to THC is between about 50:1 and about 1:1. In certain variations, the weight ratio of CBD to CBG is 3 ^sf-6205389 776772000640 between about 1:0.016-0.15. In certain variations, the weight ratio of CBD to THC is between about 1:0.003-0.03. [0016] In some variations, the CBD is greater than half of the cannabinoids present in the composition by weight. In certain variations, the CBD is greater than 49% by weight, or between 49% and 98% by weight of the cannabinoids present in the composition. In other variations, the combination of CBD and CBG is greater than half of the cannabinoids present in the composition by weight. [0017] In some variations, the CBD is greater than 5 mg/ml, between about 50 mg/ml and 150 mg/ml, or between about 5mg/ml and 500 mg/ml in the total composition; and the CBG is between about 5 mg/ml and 95 mg/ml, between about 5 mg/ml and 50 mg/ml, between about 5 mg/ml and 20 mg/ml, or between about 2.5 mg/l and 7.5 mg/ml in the total composition. In certain variations, the CBD is between about 50 mg/ml and 150 mg/ml. In certain variations, the CBG is between about 2.5 mg/ml and 7.5 mg/ml in the total composition. In a variation of the foregoing, the “total composition” includes cannabinoids, non-cannabinoids (e.g., terpenes, if present), and a vehicle (e.g., lipid vehicle). [0018] It should be understood that any suitable methods and techniques known in the art may be employed to measure the amounts of the components in the compositions. For example, gravimetric or volumetric methods may be employed to quantify the components present in the composition. One of skill in the art would appreciate how to convert the mg/ml units to other suitable units, such as mg/g. [0019] In other variations, the CBD is greater than 1% by weight, or between 1% and 90% by weight of the total composition; and the CBG is greater than 0.3% by weight, or between 0.3% and 49% by weight of the total composition. In a variation of the foregoing, the “total composition” includes cannabinoids, non-cannabinoids (e.g., terpenes, if present), and a vehicle (e.g., lipid vehicle). [0020] In some variations, the THC is present in an amount less than the limit set forth by the appropriate regulatory agencies, including for example, the U.S. Food and Drug Administration (FDA) or the U.S. Drug Enforcement Administration (DEA) or the United States Department of Agriculture (USDA) (e.g., with respect to the 2018 Farm Bill for Hemp products). In certain variations, the THC is less than 0.3% by weight, or between 0.05 % and 0.3% by weight of the cannabinoids present in the composition. In certain variations, the 4 ^sf-6205389 776772000640 THC is less than 2 mg/ml, or between about 0.5 mg/ml and 1.5 mg/ml in the total composition. In a variation of the foregoing, the “total composition” includes cannabinoids, non-cannabinoids (e.g., terpenes, if present), and a vehicle (e.g., lipid vehicle). [0021] In some embodiments, the CBD is about 100 mg/ml, the CBG is about 5 mg/ml, and the THC is about 1 mg/ml. In some variations of the foregoing, the THC is less than 0.3% by weight of the cannabinoids present in the composition. In certain variations, the minor cannabinoids are less than about 5%, less than about 2.5%, or less than about 1% by weight of the cannabinoids present in the composition. [0022] In some embodiments, the cannabinoid compositions provided herein further comprise additional components, including other cannabinoids and/or non-cannabinoids. For example, in some variations, the composition further comprises one or more of the following: cannabidiolic acid (CBDA), tetrahydrocannabinolic acid (THCA), cannabichromene (CBC), and terpenes (such as alpha-bisabolol, guaiol, beta-caryophyllene, caryophyllene oxide, alpha-humulene or alpha-caryophyllene, limonene, linalool, beta-myrcene, trans-nerolidol, (E)-b-ocimene, alpha-pinene, beta-pinene, terpineols, terpnolene, and valencene). [0023] In other variations, the composition further comprises one or more of the following: cannabinol (CBN), cannabichromene (CBC), tetrahydrocannabivarin (THCV), cannabigerolic acid (CBGA), cannabichromene acid (CBCA), cannabichromene acid (CBCA), tetrahydrocannabinolic acid (THCA), and cannabidiolic acid (CBDA), or any derivatives thereof. [0024] In other embodiments, the composition may further comprise one or more of the following compounds: • Cannabigerol-type compounds: cannabigerol ((E)-CBG C-5), cannabigerol monomethyl ether ((E)-CBGM C-5A), Cannabinerolsäure A ((Z)-CBGA C-5A), Cannabigerovarin (((e)-BGV C-3), Cannabigerolsäure A(e)-CBGA C-5A), A Cannabigerolsäure monomethyl ether ((e)-CBGAM C-5A), Cannabigerovarinsäure A ((e)-CBGVA-C3A); • Cannabichromene-type compounds: cannabichromene (CBC-C5), Cannabichromensäure A (CBCA C-5A), Cannabichromevarin (CBCVC-3), Cannabichromevarinsäure A (CBCVA-C3A); 5 ^sf-6205389 776772000640 • Cannabidiol-type compounds: cannabidiol (CBD-C5), cannabidiol monomethyl (CBDM- C5), cannabidiol-C4 (CBD-C4), Cannabidivarin (CBDV-C3), Cannabidiorcol (CBD-C1), cannabidiolic (CBDA C-5), Cannabidivarinsäure (CBDVA C-3); • Cannabinodiol-type compounds: Cannabinodiol (CBND C-5), Cannabinodivarin (CBND C-3); • Tetrahydrocannabinol-type compounds: Δ⁹-tetrahydrocannabinol (Δ⁹-THC-C5), Δ⁹- tetrahydrocannabinol-C4 (Δ⁹-THC-C4), Δ⁹-tetrahydrocannabivarin (Δ⁹-THCV-C3), Δ⁹- Tetrahydrocannabiorcol (Δ⁹-THCO C-1), Δ⁹-Tetrahydrocannabinolsäure (Δ⁹ THCA-C- 5A), Δ⁹-Tetrahydrocannabinolsäure B (Δ⁹ THCA-C-5B), Δ⁹-Tetrahydrocannabinolsäure- C4 (Δ⁹ THCA-C-4A and/or B), Δ⁹-Tetrahydrocannabivarinsäure A (Δ⁹-THCVA-C3A), Δ⁹-Tetrahydrocannabiorcolsäure (Δ⁹-THCOA-C1 A and/or B), (-)-Δ⁸-trans-(6aR, 10aR)- 8-tetrahydrocannabinol (Δ⁸-THC-C5), (-)-Δ⁸-trans-(6aR, 10aR)- Tetrahydrocannabinolsäure A (Δ⁸-THCA-C 5A); (-)-(6a S, 10a R)-Δ⁹- tetrahydrocannabinol ((-)-cis-Δ⁹-THC-C5); • Cannabinol-type compounds: Cannabinol CBN-C5, cannabinol C4 (CBN-C4), Cannabivarin (CBN-C3), cannabinol C2 (CBN-C2), Cannabiorcol (CBN-C1), Cannabinolsäure A (C5 CBNA-A), Cannabinolmethylether (CBNM C-5); • Cannabitriol-type compounds: (-)-(9R,10R)-trans-Cannabitriol ((-)-trans-CBT-C5), (+)- (9S,10S)-Cannabitriol ((+)-trans-CBT C-5), (±)-(9R, 10S/9S, 10R)-Cannabitriol ((±)-cis- CBT-C5), (-)-(9R,10R)-trans [10-0-thyl-cannabitriol] ((-)-trans-CBT-OEt-C5), (±)-(9R, 10R/9S, 10S)-Cannabitriol-C3 ((±)-trans-CBT-C3), 8,9-dihydroxy-Δ6a (10a) tetrahydrocannabinol (8,9-di-OH-CBT-C5), cannabidiolic A (CBDA C-59-OH-CBT-C5 ester), (-)-(6aR, 9S, 10S, 10aR)-9,10-dihydroxy-hexahydrocannabinol, Cannabiripsol Cannabiripsol-C5, (-)-6a,7,10a-trihydroxy-Δ⁹-tetrahydrocannabinol ((-)-Cannabitetrol), 10-oxo-Δ6a (10a) tetrahydrocannabinol (OTHC); • Cannabielsoin-type compounds: (5aS, 6S, 9R, 9aR)-C5-Cannabielsoin (CBEC-5), (5aS, 6S, 9R, 9aR)-C3-Cannabielsoin (CBE C-3), ( 5aS, 6S, 9R, 9aR)-Cannabielsoinsäure A (CBEA-C5 A), (5aS, 6S, 9R, 9aR)-Cannabielsoinsäure B (CBEA-C5 B), (5aS, 6S, 9R, 9aR)-C3 Cannabielsoinsäure B (CBEA-C3 B), Cannabiglendol-C3 (OH-iso-HHCV C-3), Dehydrocannabifuran (DCBF C-5), Cannabifuran (CBF-C5); 6 ^sf-6205389 776772000640 • Isocannabinoide-type compounds: (-)-Δ⁷-trans-(1R, 3R, 6R)Isotetrahydrocannabinol, (±) - Δ⁷-1,2-cis- (1R, 3R, 6S/1S, 3S, 6R)-Isotetrahydrocannabivarin, (-)-Δ7-trans-(1R, 3R, 6R)-Isotetrahydrocannabivarin; • Cannabicyclol-type compounds: (±)-(1aS, 3aR, 8bR, 8Cr-cannabicyclol (CBL-C), (±)- (1aS, 3aR, 8bR, 8Cr-Cannabicyclolsäure A (CBLA-C5A) (±)-(1aS, 3aR, 8bR, 8Cr- Cannabicyclovarin (CBLV C-3); • Cannabicitran-type compounds: Cannabicitran (CBT-C5); and • Cannabichromanon-type compounds: Cannabichromanon (CBCN C-5), Cannabichromanon-C3 (CBCN C-3), Cannabicoumaronon (CBCON C-5). [0025] In addition to the above cannabinoids, the carboxylic acids which are biosynthetic precursors of each are contemplated as cannabinoids that may be present in the compositions described herein. In such instances, such cannabinoids are present as a minor component in the composition. In some variations, the cannabinoid precursors are not present in a detectable amount in the composition. [0026] In some variations, minor cannabinoids present are collectively less than about 5% or less than about 2.5% by weight of the total composition. In a variation of the foregoing, the “total composition” includes cannabinoids, non-cannabinoids (e.g., terpenes, if present), and a vehicle (e.g., lipid vehicle). [0027] In other variations, the compositions further comprise terpenes. Examples of terpenes that may be detected in the compositions include, for example, alpha-bisabolol, guaiol, beta-caryophyllene, caryophyllene oxide, alpha-humulene or alpha-caryophyllene, limonene, linalool, beta-myrcene, trans-nerolidol, (E)-b-ocimene, alpha-pinene, beta-pinene, terpineols, terpnolene, and valencenealpha-bisabolol, beta-caryophyllene oxide, and guaiol. In one variation, depending on the source of the cannabinoids as described in further detail below, no detectable amounts of terpenes may be found. [0028] In yet other variations, the composition further comprises flavonoids. In one variation, depending on the source of the cannabinoids as described in further detail below, no detectable amounts of flavonoids may be found. 7 ^sf-6205389 776772000640 [0029] It should be understood that the minor cannabinoids, terpenes and flavonoids, if present in the composition, may be from the BDS and/or extracts used to provide the CBD, CBG and THC, and such sources are described in further detail below. Source of CBD, CBG and THC [0030] In some embodiments of the cannabinoid compositions provided herein, the CBD, CBG and THC are provided as a combination of extracts or isolated from at least two cannabis cultivars. [0031] In some variations when the compositions comprise a combination of BDS, extracts or blended extracts (as described in further detail below), such compositions are polymodal compositions that include multiple active components that affect multiple targets and implicate multiple mechanisms of action simultaneously. The polymodality of such compositions may positively affect efficacy and safety profile. Such polymodal compositions may be viewed as distinct from fixed dose combinations (“FDCs”) that typically will use highly purified or isolated cannabinoid components. BDS [0032] In some embodiments, one or more of CBD, CBG and THC are provided in the form a botanical drug substance (BDS). In some variations, the CBD, CBG and THC are each in the form of BDS. In some variations, a “botanical drug substance” or “BDS” is defined in the Guidance for Industry Botanical Drug Products Draft Guidance, August 2000, US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research as: “A drug derived from one or more plants, algae, or microscopic fungi. It is prepared from botanical raw materials by one or more of the following processes: pulverisation, decoction, expression, aqueous extraction, ethanolic extraction or other similar processes.” A botanical drug substance does not include a highly purified or chemically modified substance derived from natural sources. Thus, in the case of cannabis, BDS derived from cannabis plants do not include highly purified pharmaceutical grade cannabinoids. [0033] In some embodiments, the cannabinoid composition consists essentially of CBD, CBG and THC, in the form of botanical drug substance, wherein CBD, CBG and THC collectively a major component of the cannabinoids present in the composition, in the ratios and amounts as described herein. 8 ^sf-6205389 776772000640 Extracts [0034] In other embodiments, one or more of CBD, CBG and THC are provided as extracts from the cannabis plant. Such extracts may be obtained using any suitable methods and techniques known in the art. For example, dried cannabis flowers are soaked in water or alcohol to obtain the trichomes from the plant. The trichomes undergo solvent extraction and optionally additional purification steps to obtain a cannabinoid-rich oil, also referred to as an “extract”. [0035] In some variations, the CBD, CBG and THC are provided as a combination of cannabis extracts or isolated from 2-4 cannabis cultivars. In certain variations, the CBD, CBG and THC are provided as a combination of cannabis extracts from genetically identical clones of 3 different cannabis cultivars. In one variation for the foregoing, the 3 different cultivars are a high CBD cultivar, a high CBG cultivar and a high THC cultivar. In some variations, the cannabis cultivars are Cannabis sativa cultivars. [0036] In some variations, when the CBD, CBG and THC are provided as extracts, the compositions provided herein further include terpenes. In certain variations, when the CBD, CBG and THC are provided as extracts, the compositions provided herein further include terpenes and flavonoids. Blended Extracts [0037] In other embodiments, one or more of the CBD, CBG and THC are provided as a blend of the extracts described above in combination with additional CBD, CBG and/or THC obtained from other sources to achieve the particular ratios and amounts of CBD, CBG and THC as described herein. For example, in some variations, the composition comprises CBD, CBG and THC provided as extracts from the cannabis plants, blended with additional CBD provided in a purified form or as an isolate to achieve the ratios and amounts of CBD, CBG and THC as described herein. Purified Forms [0038] In yet other embodiments, one or more of the CBD, CBG and THC are provided in a purified form. Such purified forms of the cannabinoids may be obtained using any suitable methods and techniques known in the art. For example, the extract or blended 9 ^sf-6205389 776772000640 extracts described above may undergo distillation (e.g., molecular distillation) to remove certain constituents, such as terpenes and lipids, that are non-cannabinoids, and also separate out specific cannabinoids. In some variations, the purified extracts are oils. [0039] In certain variations, the CBD, CBG and THC are a combination of highly purified CBD, highly purified CBG and highly purified THC, wherein each of which are extracted from a cannabis plant and purified to the extent that other cannabinoids and a majority of non-cannabinoid components that are co-extracted with the cannabinoids have been removed. In one variation, the highly purified CBD is greater than or equal to 90% (w/w) pure; the highly purified CBG is greater than or equal to 90% (w/w) pure; and the highly purified THC is greater than or equal to 90% (w/w) pure. Isolates [0040] In some variations, one or more CBD, CBG and THC are provided as isolates. Such isolates may be obtained using any suitable methods and techniques known in the art. For example, the isolates may be obtained by crystallization or precipitation of a purified extract as described above to isolate a specific cannabinoid, followed by filtration to yield a powder that is essentially a pure cannabinoid with excess solvent removed. In some variations the isolates are powders. In one variation, the CBD isolate is greater than or equal to 99% (w/w) pure; the CBG isolate is greater than or equal to 99% (w/w) pure; and the THC isolate is greater than or equal to 99% (w/w) pure. [0041] In certain variations, CBD, CBG and THC are provided a combination of isolates, which may be with or without BDS, extracts or blended extracts. In one variation, the CBD, CBG and THC are provided as a combination of isolates and BDS. Natural vs. Synthetic Sources [0042] In some variations, the CBD, CBG and THC are all naturally derived. In other variations, at least a portion of the CBD, CBG and/or THC is naturally derived, and the other portion is synthetic and/or biosynthetic. Synthetic cannabinoids may include compounds that have a cannabinoid-like structure and are manufactured using chemical processes rather than by the plant. Biosynthetic cannabinoids may include compounds that have a cannabinoid- like structure and are produced using biological processes rather than by the plant. In certain embodiments, at least a portion of CBD present in the composition is prepared synthetically 10 ^sf-6205389 776772000640 or biosynthetically. In certain embodiments, at least a portion of CBG present in the composition is prepared synthetically or biosynthetically. In certain embodiments, at least a portion of THC present in the composition is prepared synthetically or biosynthetically. [0043] It should be understood that the compositions provided herein may include CBD, CBG and THC provided in a combination of different forms described above. For example, in certain variations, the CBD, CBG and THC are provided in the form of BDS in combination with additional refined or synthetic or biosynthetic CBD, CBG and THC to achieve the ratios and amounts described herein. Lipid Vehicles [0044] In some embodiments, the combination of cannabinoids described herein are formulated in lipid vehicles to yield the compositions, e.g., the drug formulation. In some variations, the compositions herein may further comprise at least one lipid excipient. In certain variations, suitable excipients may include glyceryl monolinoleate. [0045] In some variations, the lipid vehicle comprises a winterized oil composed of long- chain mono-, di-, and triglycerides. In certain variations, the lipid vehicle comprises mono-, di- and triglycerides of mainly linoleic (C_18:2) and oleic (C_18:1) acids. In one variation of the foregoing, the diester fraction is predominant. [0046] In other embodiments, the lipid vehicle comprises self-emulsifying drug delivery systems. Other Components [0047] In other embodiments, the compositions provided herein may further include or more additional components. For example, in some variations, the compositions further comprise at least one fatty acid. In certain variations, the compositions further comprise long-chain omega-3 polyunsaturated fatty acids (O-3s). In one variation, the compositions further comprise docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). [0048] In some embodiments, the drug substance compositions comprise (i) CBD, CBG and THC, collectively a major component of the cannabinoids present in the composition, in the ratios and amounts as described herein, (ii) fats and fatty acids, and (iii) terpenes. In certain embodiments, the drug substance consists essentially of (i) CBD, CBG and THC, 11 ^sf-6205389 776772000640 collectively a major component of the cannabinoids present in the composition, in the ratios and amounts as described herein; (ii) fats and fatty acids; and (iii) terpenes. [0049] In some variations, the drug substance compositions comprise (i) between 70% and 90% cannabinoids, including CBD, CBG and THC, collectively a major component of the cannabinoids present in the composition, in the ratios and amounts as described herein, (ii) between 10% and 15% fats and fatty acids, and (iii) between 1% and 5% terpenes. For example, in one variation, the composition comprises (i) about 80% cannabinoids in the ratios and amounts as described herein, (ii) about 15% fats and fatty acids, and (iii) about 5% terpenes. In certain variations, the drug substance compositions consist essentially of (i) between 70% and 90% cannabinoids in the ratios and amounts as described herein, (ii) between 10% and 15% fats and fatty acids, and (iii) between 1% and 5% terpenes. [0050] In some embodiments, the drug product compositions comprise (i) CBD, CBG and THC, collectively a major component of the cannabinoids present in the composition, in the ratios and amounts as described herein, (ii) fats and fatty acids, (iii) terpenes, and (iv) at least one lipid, such as a winterized oil composed of long-chain mono-, di-, and triglycerides. In certain embodiments, the drug product compositions consist essentially of (i) CBD, CBG and THC, collectively a major component of the cannabinoids present in the composition, in the ratios and amounts as described herein, (ii) fats and fatty acids; terpenes, (iii) and at least one lipid, such as a winterized oil composed of long-chain mono-, di-, and triglycerides. Preparation Methods [0051] The cannabinoid compositions provided herein may be obtained from combining plant-derived, synthetic and/or biosynthetic CBD, CBG and THC, in order to achieve the appropriate amounts and ratios of these components. [0052] As discussed above, when CBD, CBG and THC are plant-derived, they may be obtained from a cannabis plant. Various methods, techniques and conditions to cultivate, harvest and process cannabis plants are generally known in the art. Further, the resulting cannabis extract may be characterized using methods known in the art. Any suitable processes known in the art may be employed to obtain the CBD, CBG and THC used herein. [0053] For example, bulk plant material is isolated from dried cannabis flower. The bulk plant material is separated from the botanical starting material. The botanical starting 12 ^sf-6205389 776772000640 materials are weighed and stored in an amber jar. The botanical starting material are added to an extraction vessel with solvent. The solvent is removed via vacuum distillation until only refined cannabis oil is present, with a low solvent concentration. The crude cannabis oil is then heated to for a suitable time to convert the THCA to THC to yield a refined cannabis oil. The main cannabinoids, THCA, CBDA and CBGA are converted to the base molecule THC, CBD and CBG, respectively. [0054] The cannabinoid extracts described above may undergo further purification using methods and techniques known in the art to obtain purified extracts or isolates. The purified extracts are typically in oil form, whereas the isolates are typically in powder form. In some variations, cannabis extracts may undergo distillation to remove certain constituents, such as terpenes and lipids, that are non-cannabinoids, and also separate out specific cannabinoids to yield a purified extract. In other variations, such purified extract may undergo crystallization or precipitation to isolate a specific cannabinoid, followed by filtration to yield a powder that is essentially a pure cannabinoid with excess solvent removed. [0055] The cannabinoid compositions provided herein are pharmaceutical cannabinoid compositions, formulated based on the mode of intended administration. For example, in some embodiments, administration may be ocular, oral, parenteral, topical, etc. In one variation, the cannabinoid composition is formulated for oral administration. In some embodiments, the cannabinoid composition is formulated as a solution for oral administration. In some embodiments, the composition may further comprise one or more flavoring or masking agents, including agents that may mask bitterness of the composition (e.g., any bitterness from the BDS). [0056] In some embodiments, the cannabinoid compositions may be formulated with one or more excipients to increase stability, increase shelf-life, or increase efficacy. Cannabinoid compositions disclosed herein may be formulated for administration according to methods known in the art. Treatment Methods [0057] In some aspects, provided is a method for treating post-traumatic epilepsy (PTE) in a subject in need thereof. In some variations of the foregoing aspects, the subject is a human. In one variation, the subject is an adult human. 13 ^sf-6205389 776772000640 [0058] In some embodiments of the foregoing aspects, the method comprises administering to the subject the compositions described herein, e.g., comprising CBD, CBG and THC as the major components therein. In some variations of the foregoing aspects, the terms “treating” or “treatment”, as used herein, refer to a method or procedure for obtaining beneficial or desired results—for example, clinical results. Beneficial or desired results may include: (1) alleviating one or more symptoms caused by or associated with a disease, disorder, or condition; (2) reducing the extent of the disease, disorder, or condition; (3) slowing or stopping the development or progression of one or more symptoms caused by or associated with the disease, disorder, or condition (for example, stabilizing the disease, disorder, or condition); and (4) relieving the disease, for example, by causing the regression of one or more clinical symptoms (e.g., ameliorating the disease state, enhancing the effect of another medication, delaying or stopping the progression of the disease, increasing the quality of life, and/or prolonging survival rates). [0059] In some variations, the treatment decreases the frequency of occurrence of seizures in the human. In some variations, the treatment decreases the severity of seizures in the human. In some variations, the treatment reduces anxiety in the human. In some variations, the treatment improves mood in the human. In some variations, the treatment improves sleep quality in the human. In certain embodiments, the treatment reduces the amount and/or frequency of antiepileptic drug and/or rescue medication concomitantly administered to the human. [0060] In certain aspects, provided is a method for treating post-traumatic epilepsy (PTE) in a human in need thereof, comprising: a) administering to the human a cannabinoid composition as described herein; and b) decreasing the frequency of occurrence of seizures in the human. In certain aspects, provided is a method for treating post-traumatic epilepsy (PTE) in a human in need thereof, comprising: a) administering to the human a cannabinoid composition as described herein; and b) decreasing the severity of seizures in the human. In certain aspects, provided is a method for treating post-traumatic epilepsy (PTE) in a human in need thereof, comprising: a) administering to the human a cannabinoid composition as described herein; and b) reducing anxiety in the human. In certain aspects, provided is a method for treating post-traumatic epilepsy (PTE) in a human in need thereof, comprising: a) administering to the human a cannabinoid composition as described herein; and b) improving mood in the human. In certain aspects, provided is a method for treating post-traumatic 14 ^sf-6205389 776772000640 epilepsy (PTE) in a human in need thereof, comprising: a) administering to the human a cannabinoid composition as described herein; and b) improving sleep quality in the human. [0061] In some embodiments of the methods described herein, the human is concomitantly taking an antiepileptic drug and/or rescue medication. In other embodiments of the methods described herein, the method further comprising concomitantly administering an antiepileptic drug and/or rescue medication to the human. In some variations, rescue medications are approved as an acute treatment, and given at the time of the seizure or during periods of frequent seizures. They may be used to treat cluster seizures or seizures that are distinct from the person’s usual seizure patterns. In one variation, suitable rescue medications may include, for example, Diastat AcuDial (rectal diazepam), Nayzilam (intranasal midazolam), and Valtoco (intranasal diazepam). [0062] In some variations, the PTE is refractory PTE. In certain variations, refractory PTE is defined as a failure of adequate trials of two tolerated, appropriately chosen and used antiepileptic drug schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom for PTE patients. [0063] In some variations, the human suffers from drug-resistant PTE. In certain variations, the human suffers from debilitating drug-resistant PTE. [0064] In some variations, the pharmaceutical cannabinoid composition is administered daily. In other variations, the pharmaceutical cannabinoid composition is administered twice daily. In some variations, the cannabinoid composition is administered with food. In some variations, the cannabinoid composition is administered without food. [0065] In some variations of the foregoing aspects, a therapeutically effective amount of the cannabinoid composition is administered. In certain variations, the term “therapeutically effective amount” applied to dose or amount refers to that quantity of a composition or formulation, such as those described herein, that is sufficient to result in a desired clinical benefit after administration to a subject in need thereof. It is to be understood that the amount may be in one or more doses, e.g., a single dose or multiple doses pharmaceutical may be needed to achieve the desired treatment endpoint. In some variations, the cannabinoid composition is administered at a dose between 100 mg and 1500 mg. In certain variations, the cannabinoid composition is administered at a dose of 200 mg daily or 100 mg twice daily. In other variations, the cannabinoid composition is administered at a dose of 800 mg daily or 15 ^sf-6205389 776772000640 400 mg twice daily. In yet other variations, the cannabinoid composition is administered at a dose of 1500 mg daily or 750 mg twice daily. It should be understood that dose here is measured against the amount of CBD. [0066] In some embodiments, the cannabinoid composition is administered at a therapeutically effective dose. In some variations, the term “therapeutically effective” applied to dose or amount refers to that quantity of the cannabinoid composition, such as those described elsewhere herein, that is sufficient to result in a desired clinical benefit after administration to a subject in need thereof. It is to be understood that an effective amount may be in one or more doses, e.g., a single dose or multiple doses may be needed to achieve the desired treatment endpoint. [0067] In certain aspects, provided is a composition as described herein, e.g., comprising CBD, CBG and THC as the major components therein, for use in a method of treating post- traumatic epilepsy (PTE). In some variations, provided is a composition as described herein, e.g., comprising CBD, CBG and THC as the major components therein, for use in a method of treating post-traumatic epilepsy (PTE) in any of the doses described herein, including in a dose between 100 mg and 1500 mg, a 200 mg daily dose, a 100 mg twice daily dose, a 800 mg daily dose, a 400 mg twice daily dose, 1500 mg daily dose, or a 750 mg twice daily dose. It should be understood that dose here is measured against the amount of CBD. [0068] In some variations, provided is a composition as described herein, e.g., comprising CBD, CBG and THC as the major components therein, for use in a method of treating post- traumatic epilepsy (PTE), wherein the frequency of occurrence of seizures is decreased, the severity of seizures is decreased, anxiety is reduced, mood improves, or sleep quality improves, or any combination of the foregoing outcomes. [0069] In some variations, provided is a composition as described herein, e.g., comprising CBD, CBG and THC as the major components therein, for use in a method of treating post- traumatic epilepsy (PTE), wherein the method comprises administering the composition concomitantly with an antiepileptic drug and/or rescue medication. In certain variations, the amount and/or frequency of antiepileptic drug and/or rescue medication concomitantly administered is reduced. [0070] In some variations, provided is a composition as described herein, e.g., comprising CBD, CBG and THC as the major components therein, for use in a method of 16 ^sf-6205389 776772000640 treating post-traumatic epilepsy (PTE) in a specific patient population suffering from refractory PTE. In other variations, provided is a composition as described herein, e.g., comprising CBD, CBG and THC as the major components therein, for use in a method of treating post-traumatic epilepsy (PTE) in a specific patient population suffering from drug- resistant PTE, or in one variation, suffering from debilitating drug-resistant PTE. [0071] In some variations, the cannabinoid composition is administered at an initial dose between about 100 mg and about 150 mg, wherein the dose is measured against the amount of CBD in the composition. In one variation, the initial dose administered is about 100 mg of the cannabinoid composition. In certain variations, the aforementioned initial doses may be administered once a day or twice a day. [0072] In some embodiments, the initial dose of the cannabinoid composition is between 200 mg and 300 mg total daily dose. In certain embodiments, the initial dose of the cannabinoid composition is 200 mg total daily dose. In some variations, the subject is monitored for clinical response and tolerability of the cannabinoid composition administered. In some variations, the dose of the cannabinoid composition administered to the subject is increased up to a maximum total daily dose of about 1000 mg, about 800 mg, about 700 mg, about 600 mg, about 500 mg, about 400 mg, or about 300 mg. The dose may be titrated up based on safety and desired effect experienced by the subject. In some variations of the foregoing, the total daily dose noted above may be administered once a day, or twice a day. [0073] In one aspect, provided is a method of treating post-traumatic epilepsy (PTE) in a human in need thereof that comprises administering a cannabinoid composition as described herein at a therapeutically effect amount. In one embodiment, the method comprises administering a cannabinoid composition as described herein at an initial dose of about 100 mg; monitoring safety and effect on PTE, or the symptoms of PTE, experienced by the subject; and administering an increased dose of the cannabinoid composition, wherein the increased dose is up to a maximum total daily dose of about 1000 mg, about 1000 mg, about 800 mg, about 700 mg, about 600 mg, about 500 mg, about 400 mg, or about 300 mg. In one variation of the foregoing, the total daily dose is administered in one daily dose. In another variation of the foregoing, the total daily dose is administered twice a day (e.g., in two doses). 17 ^sf-6205389 776772000640 Kits and Articles of Manufacture [0074] In other aspects, the present disclosure further provides kits for carrying out the methods of the invention. The kits may comprise the cannabinoid compositions described herein and suitable packaging. In some embodiments, provided is a kit, comprising: (i) any of the cannabinoid compositions described herein; and (ii) a label and/or instructions for use in treating PTE. In one variation of the foregoing, the total daily dose is administered in one daily dose. In another variation of the foregoing, the total daily dose is administered twice a day (e.g., in two doses). [0075] In yet other aspects, the present disclosure further provides an article of manufacture, comprising any of the cannabinoid compositions described herein in a suitable container. In one variation of the foregoing, the total daily dose is administered in one daily dose. In another variation of the foregoing, the total daily dose is administered twice a day (e.g., in two doses). ENUMERATED EMBODIMENTS [0076] The following enumerated embodiments are representative of some aspects of the invention. 1A. A method of treating post-traumatic epilepsy (PTE) in a human in need thereof, comprising: administering a cannabinoid composition comprising: cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC), collectively a major component of the cannabinoids present in the composition, wherein the CBD, CBG and THC are provided as a combination of extracts or isolated from at least two cannabis cultivars. 2A. The method of embodiment 1A, wherein the CBD, CBG and/or THC are provided as botanical drug substances (BDS). 3A. The method of embodiment 2A, wherein the cannabinoid composition further comprises other cannabinoid and/or non-cannabinoid components that are present from the BDS. 18 ^sf-6205389 776772000640 4A. The method of embodiment 2A, wherein the cannabinoid composition further comprises terpenes that are present from the BDS. 5A. The method of any one of embodiments 2A to 4A, wherein the cannabinoid composition further comprises flavonoids that are present from the BDS. 6A. The method of embodiment 1A, wherein the CBD, CBG and THC are provided as a combination of cannabis extracts. 7A. The method of embodiment 1A, wherein the CBD, CBG and THC are provided as a combination of extracts from 2-4 cannabis cultivars. 8A. The method of embodiment 1A, wherein the CBD, CBG and THC are provided as a combination of extracts from genetically identical clones of 3 different cannabis cultivars. 9A. The method of embodiment 8A, wherein the 3 different cannabis cultivars are a high CBD cultivar, a high CBG cultivar and a high THC cultivar. 10A. The method of any one of embodiments 7A to 9A, wherein cannabis cultivars are Cannabis sativa cultivars. 11A. The method of any one of embodiments 6A to 10A, wherein the cannabinoid composition further comprises other cannabinoid and/or non-cannabinoid components that are present from the extracts. 12A. The method of any one of embodiments 6A to 10A, wherein the cannabinoid composition further comprises terpenes that are present from the extracts. 13A. The method of any one of embodiments 6A to 11A, wherein the cannabinoid composition further comprises flavonoids that are present from the extracts. 14A. The method of any one of embodiments 2A to 13A, wherein the cannabinoid composition further comprises additional CBD, CBG and/or THC provided in purified form. 15A. The method of any one of embodiments 2A to 13A, wherein the cannabinoid composition further comprises additional CBD, CBG and/or THC isolates. 16A. The method of embodiment 1A, wherein the CBD, CBG and THC are provided as a combination of purified CBD, CBG and THC cannabis extracts. 19 ^sf-6205389 776772000640 17A. The method of embodiment 1A, wherein the CBD, CBG and THC are provided as a combination of CBD, CBG and THC isolates. 18A. The method of embodiment 1A, wherein the CBD, CBG and THC are provided as a combination of BDS and CBD, CBG and/or THC isolates. 19A. The method of embodiment 1A, wherein the CBD, CBG and THC are provided as a combination of BDS, and purified CBD, CBG and/or THC cannabis extracts. 20A. The method of embodiment 1A, wherein the CBD, CBG and THC are provided as a combination of BDS, and CBD, CBG and/or THC isolates. 21A. The method of embodiment 1A, wherein the CBD, CBG and THC are provided as BDS in combination with refined or synthetic CBD, CBG and/or THC. 22A. The method of embodiment 1A, wherein the CBD, CBG and THC are a combination of highly purified CBD, highly purified CBG and highly purified THC, wherein each of which are extracted from a cannabis plant and purified to the extent that other cannabinoids and a majority of non-cannabinoid components that are co-extracted with the cannabinoids have been removed. 23A. The method of embodiment 22A, wherein the highly purified CBD is greater than or equal to 90% (w/w) pure; the highly purified CBG is greater than or equal to 90% (w/w) pure; and the highly purified THC is greater than or equal to 90% (w/w) pure. 24A. The method of embodiment 1A, wherein the CBD, CBG and THC are all naturally derived. 25A. The method of embodiment 1A, wherein at least a portion of the CBD, CBG and/or THC is naturally derived, and the other portion is synthetic and/or biosynthetic. 26A. The method of any one of the preceding embodiments, wherein the THC is present primarily in the form of (–)-delta-9-trans-tetrahydrocannabinol (Δ9-THC). 27A. The method of any one of the preceding embodiments, wherein the CBD, CBG and THC are collectively greater than 50% by weight of the cannabinoids present in the composition. 20 ^sf-6205389 776772000640 28A. The method of embodiment 27A, wherein the CBD, CBG and THC are collectively greater than 60% by weight of the cannabinoids present in the composition. 29A. The method of any one of the preceding embodiments, wherein the CBD, CBG and THC are present in a molar ratio between about 100:100:1 and about 1:1:1. 30A. The method of embodiment 29A, wherein the CBD, CBG and THC are present in a molar ratio is between about 100:50:1 and about 20:1:1. 31A. The method of any one of the preceding embodiments, wherein the CBD and CBG are present in a molar ratio between about 100:1 and about 1:1. 32A. The method of any one of the preceding embodiments, wherein the molar ratio of CBD and THC is between about 50:1 and about 1:1. 33A. The method of any one of the preceding embodiments, wherein the cannabinoid composition further comprises at least one lipid excipient. 34A. The method of embodiment 33A, wherein at least one lipid excipient is a winterized oil comprising long-chain mono-, di-, and triglycerides. 35A. The method of any one of the preceding embodiments, wherein the cannabinoid composition further comprises docosahexaenoic acid (DHA), or eicosapentaenoic acid (EPA), or a combination thereof. 36A. The method of any one of the preceding embodiments, wherein the composition is formulated for oral delivery, and optionally wherein the composition further comprises one or more flavoring or masking agents. 37A. The method of any one of the preceding embodiments, wherein the PTE is refractory PTE. 38A. The method of any one of the preceding embodiments, wherein the treatment decreases the frequency of occurrence of seizures in the human. 39A. The method of any one of the preceding embodiments, wherein the treatment decreases the severity of seizures in the human. 21 ^sf-6205389 776772000640 40A. The method of any one of the preceding embodiments, wherein the treatment reduces anxiety in the human. 41A. The method of any one of the preceding embodiments, wherein the treatment improves mood in the human. 42A. The method of any one of the preceding embodiments, wherein the treatment improves sleep quality in the human. 43A. The method of any one of the preceding embodiments, wherein the human concomitantly takes an antiepileptic drug and/or rescue medication. 44A. The method of embodiment 43A, wherein the treatment reduces the amount and/or frequency of the antiepileptic drug and/or rescue medication concomitantly administered to the human. 45A. The method of any one of the preceding embodiments, wherein the human suffers from drug-resistant PTE. 46A. The method of any one of the preceding embodiments, wherein the human suffers from debilitating drug-resistant PTE. 47A. The method of any one of embodiments 1A to 46A, wherein the pharmaceutical cannabinoid composition is administered daily. 48A. The method of any one of embodiments 1A to 46A, wherein the pharmaceutical cannabinoid composition is administered twice daily. 49A. The method of any one of embodiments 1A to 46A, wherein the pharmaceutical cannabinoid composition is administered at a dose between 100 mg and 1500 mg. 50A. The method of any one of embodiments 1A to 46A, wherein the pharmaceutical cannabinoid composition is administered at a dose of 200 mg daily or 100 mg twice daily. 51A. The method of any one of embodiments 1A to 46A, wherein the pharmaceutical cannabinoid composition is administered at a dose of 800 mg daily or 400 mg twice daily. 52A. The method of any one of embodiments 1A to 46A, wherein the pharmaceutical cannabinoid composition is administered at a dose of 1500 mg daily or 750 mg twice daily. 22 ^sf-6205389 776772000640 53A. A cannabinoid composition, comprising: cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC), collectively a major component of the cannabinoids present in the composition, wherein the CBD is between about 90 mg/ml and 110 mg/ml, and the CBG is between about 4.5 mg/ml and 5.5 mg/ml, and wherein the CBD, CBG and THC are provided as a combination of extracts or isolated from at least two cannabis cultivars. 54A. The composition of embodiment 53A, wherein the CBD, CBG and/or THC are provided as botanical drug substances (BDS). 55A. The composition of embodiment 53A, further comprising other cannabinoid and/or non-cannabinoid components that are present from the BDS. 56A. The composition of embodiment 53A, further comprising terpenes that are present from the BDS. 57A. The composition of any one of embodiments 53A to 56A, further comprising flavonoids that are present from the BDS. 58A. The composition of embodiment 53A, wherein the CBD, CBG and THC are provided as a combination of cannabis extracts. 59A. The composition of embodiment 53A, wherein the CBD, CBG and THC are provided as a combination of extracts from 2-4 cannabis cultivars. 60A. The composition of embodiment 53A, wherein the CBD, CBG and THC are provided as a combination of extracts from genetically identical clones of 3 different cannabis cultivars. 61A. The composition of embodiment 60A, wherein the 3 different cannabis cultivars are a high CBD cultivar, a high CBG cultivar and a high THC cultivar. 62A. The composition of any one of embodiments 59A to 61A, wherein cannabis cultivars are Cannabis sativa cultivars. 63A. The composition of any one of embodiments 59A to 62A, further comprising other cannabinoid and/or non-cannabinoid components that are present from the extracts. 23 ^sf-6205389 776772000640 64A. The composition of any one of embodiments 59A to 63A, further comprising terpenes that are present from the extracts. 65A. The composition of any one of embodiments 59A to 64A, further comprising flavonoids that are present from the extracts. 66A. The composition of any one of embodiments 53A to 65A, further comprising additional CBD, CBG and/or THC provided in purified form. 67A. The composition of any one of embodiments 53A to 65A, further comprising additional CBD, CBG and/or THC isolates. 68A. The composition of embodiment 53A, wherein the CBD, CBG and THC are provided as a combination of purified CBD, CBG and THC cannabis extracts. 69A. The composition of embodiment 53A, wherein the CBD, CBG and THC are provided as a combination of CBD, CBG and THC isolates. 70A. The composition of embodiment 53A, wherein the CBD, CBG and THC are provided as a combination of BDS and CBD, CBG and/or THC isolates. 71A. The composition of embodiment 53A, wherein the CBD, CBG and THC are provided as a combination of BDS, and purified CBD, CBG and/or THC cannabis extracts. 72A. The composition of embodiment 53A, wherein the CBD, CBG and THC are provided as a combination of BDS, and CBD, CBG and/or THC isolates. 73A. The composition of embodiment 53A, wherein the CBD, CBG and THC are provided as BDS in combination with refined or synthetic CBD, CBG and/or THC. 74A. The composition of embodiment 53A, wherein the CBD, CBG and THC are a combination of highly purified CBD, highly purified CBG and highly purified THC, wherein each of which are extracted from a cannabis plant and purified to the extent that other cannabinoids and a majority of non-cannabinoid components that are co-extracted with the cannabinoids have been removed. 24 ^sf-6205389 776772000640 75A. The composition of embodiment 74A, wherein the highly purified CBD is greater than or equal to 90% (w/w) pure; the highly purified CBG is greater than or equal to 90% (w/w) pure; and the highly purified THC is greater than or equal to 90% (w/w) pure. 76A. The composition of embodiment 53A, wherein the CBD, CBG and THC are all naturally derived. 77A. The composition of embodiment 53A, wherein at least a portion of the CBD, CBG and/or THC is naturally derived, and the other portion is synthetic and/or biosynthetic. 78A. The composition of any one of the preceding embodiments, wherein the THC is present primarily in the form of (–)-delta-9-trans-tetrahydrocannabinol (Δ9-THC). 79A. The composition of any one of the preceding embodiments, further comprising at least one lipid excipient. 80A. The composition of embodiment 79A, wherein at least one lipid excipient is a winterized oil comprising long-chain mono-, di-, and triglycerides. 81A. The composition of any one of the preceding embodiments, further comprising docosahexaenoic acid (DHA), or eicosapentaenoic acid (EPA), or a combination thereof. 82A. The composition of any one of the preceding embodiments, wherein the THC is present in less than 0.3% by weight of the total composition. 83A. The composition of any one of the preceding embodiments, wherein the CBD is about 100 mg/ml, the CBD is about 5 mg/ml, and the THC is about 1 mg/ml. 84A. The composition of any one of the preceding embodiments, wherein the composition is formulated for oral delivery, and optionally wherein the composition further comprises one or more flavoring or masking agents. 85A. A composition of any one of embodiments 53A to 84A for use in treating post- traumatic epilepsy (PTE). 86A. The composition of embodiment 85A, for use in treating refractory PTE. 87A. The composition of embodiment 85A or 86A, wherein: the frequency of occurrence of seizures is decreased; or 25 ^sf-6205389 776772000640 the severity of seizures is decreased; or anxiety is reduced; or mood is improved; or sleep quality is improved; or any combination of the foregoing. 88A. The composition of any one of embodiments 85A to 87A, wherein the method comprises administering the composition concomitantly with an antiepileptic drug and/or rescue medication. 89A. The composition of embodiment 88A, wherein the amount and/or frequency of the antiepileptic drug and/or rescue medication concomitantly administered is reduced. 90A. A composition of any one of embodiments 53A to 89A for use in treating post- traumatic epilepsy (PTE) in a patient population suffering from drug-resistant PTE. 91A. The composition of embodiment 90A, wherein the patient population suffers from debilitating drug-resistant PTE. 1B. A method of treating post-traumatic epilepsy (PTE) in a human in need thereof, comprising: administering a cannabinoid composition comprising: cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC), collectively a major component of the cannabinoids present in the composition, wherein CBD, CBG and THC are provided as a combination of extracts or isolated from at least two cannabis cultivars, and wherein the weight ratio of CBD to CBG is 1 to between 0.016 and 0.15. 2B. The method of embodiment 1B, wherein the weight ratio of CBD to THC is 1:0.003- 0.03. 3B. The method of embodiment 1B or 2B, wherein CBD, CBG and/or THC are provided as botanical drug substances (BDS). 4B. The method of embodiment 3B, wherein the cannabinoid composition further comprises other cannabinoid and/or non-cannabinoid components that are present from the BDS. 26 ^sf-6205389 776772000640 5B. The method of embodiment 3B, wherein the cannabinoid composition further comprises terpenes that are present from the BDS. 6B. The method of any one of embodiments 3B to 5B, wherein the cannabinoid composition further comprises flavonoids that are present from the BDS. 7B. The method of embodiment 1B or 2B, wherein CBD, CBG and THC are provided as a combination of cannabis extracts. 8B. The method of embodiment 1B or 2B, wherein CBD, CBG and THC are provided as a combination of extracts from 2-4 cannabis cultivars. 9B. The method of embodiment 1B or 2B, wherein CBD, CBG and THC are provided as a combination of extracts from genetically identical clones of 3 different cannabis cultivars. 10B. The method of embodiment 9B, wherein the 3 different cannabis cultivars are a high CBD cultivar, a high CBG cultivar and a high THC cultivar. 11B. The method of any one of embodiments 8B to 10B, wherein cannabis cultivars are Cannabis sativa cultivars. 12B. The method of any one of embodiments 7B to 11B, wherein the cannabinoid composition further comprises other cannabinoid and/or non-cannabinoid components that are present from the extracts. 13B. The method of any one of embodiments 7B to 12B, wherein the cannabinoid composition further comprises terpenes that are present from the extracts. 14B. The method of any one of embodiments 7B to 13B, wherein the cannabinoid composition further comprises flavonoids that are present from the extracts. 15B. The method of any one of embodiments 3B to 14B, wherein the cannabinoid composition further comprises additional CBD, CBG and/or THC provided in purified form. 16B. The method of any one of embodiments 3B to 14B, wherein the cannabinoid composition further comprises additional CBD, CBG and/or THC isolates. 17B. The method of embodiment 1B or 2B, wherein CBD, CBG and THC are provided as a combination of purified CBD, CBG and THC cannabis extracts. 27 ^sf-6205389 776772000640 18B. The method of embodiment 1B or 2B, wherein CBD, CBG and THC are provided as a combination of CBD, CBG and THC isolates. 19B. The method of embodiment 1B or 2B, wherein CBD, CBG and THC are provided as a combination of BDS and CBD, CBG and/or THC isolates. 20B. The method of embodiment 1B or 2B, wherein CBD, CBG and THC are provided as a combination of BDS, and purified CBD, CBG and/or THC cannabis extracts. 21B. The method of embodiment 1B or 2B, wherein CBD, CBG and THC are provided as a combination of BDS, and CBD, CBG and/or THC isolates. 22B. The method of embodiment 1B or 2B, wherein CBD, CBG and THC are provided as BDS in combination with refined or synthetic CBD, CBG and/or THC. 23B. The method of embodiment 1B or 2B, wherein CBD, CBG and THC are a combination of highly purified CBD, highly purified CBG and highly purified THC, wherein each of which are extracted from a cannabis plant and purified to the extent that other cannabinoids and a majority of non-cannabinoid components that are co-extracted with the cannabinoids have been removed. 24B. The method of embodiment 24B, wherein the highly purified CBD is greater than or equal to 90% (w/w) pure; the highly purified CBG is greater than or equal to 90% (w/w) pure; and the highly purified THC is greater than or equal to 90% (w/w) pure. 25B. The method of embodiment 1B or 2B, wherein CBD, CBG and THC are all naturally derived. 26B. The method of embodiment 1B or 2B, wherein at least a portion of CBD, CBG and/or THC is naturally derived, and the other portion is synthetic and/or biosynthetic. 27B. The method of any one of the preceding embodiments, wherein the THC is present primarily in the form of (–)-delta-9-trans-tetrahydrocannabinol (Δ9-THC). 28B. The method of any one of the preceding embodiments, wherein CBD, CBG and THC are collectively greater than 50% by weight of the cannabinoids present in the composition. 28 ^sf-6205389 776772000640 29B. The method of embodiment 28B, wherein CBD, CBG and THC are collectively greater than 60% by weight of the cannabinoids present in the composition. 30B. The method of any one of the preceding embodiments, wherein the cannabinoid composition further comprises at least one lipid excipient. 31B. The method of embodiment 30B, wherein at least one lipid excipient is a winterized oil comprising long-chain mono-, di-, and triglycerides. 32B. The method of any one of the preceding embodiments, wherein the cannabinoid composition further comprises docosahexaenoic acid (DHA), or eicosapentaenoic acid (EPA), or a combination thereof. 33B. The method of any one of the preceding embodiments, wherein the composition is formulated for oral delivery, and optionally wherein the composition further comprises one or more flavoring or masking agents. 34B. The method of any one of the preceding embodiments, wherein the cannabinoid composition is formulated as a solution. 35B. The method of embodiment 34B, wherein CBD is between about 50 mg/ml and 150 mg/ml. 36B. The method of embodiment 35B, wherein CBD is between about 90 mg/ml and 110 mg/ml. 37B. The method of embodiments any one of embodiments 34B to 36B, wherein CBG is between about 2.5 mg/ml and 7.5 mg/ml. 38B. The method of any one of embodiments 34B to 37B, wherein THC is between about 0.5 mg/ml and 1.5 mg/ml. 39B. The method of any one of embodiments 34B to 38B, wherein CBD is about 100 mg/ml, CBG is about 5 mg/ml, and THC is about 1 mg/ml. 40B. The method of any one of the preceding embodiments, wherein the PTE is refractory PTE. 29 ^sf-6205389 776772000640 41B. The method of any one of the preceding embodiments, wherein the treatment decreases the frequency of occurrence of seizures in the human. 42B. The method of any one of the preceding embodiments, wherein the treatment decreases the severity of seizures in the human. 43B. The method of any one of the preceding embodiments, wherein the treatment reduces anxiety in the human. 44B. The method of any one of the preceding embodiments, wherein the treatment improves mood in the human. 45B. The method of any one of the preceding embodiments, wherein the treatment improves sleep quality in the human. 46B. The method of any one of the preceding embodiments, wherein the human concomitantly takes an antiepileptic drug and/or rescue medication. 47B. The method of embodiment 46B, wherein the treatment reduces the amount and/or frequency of the antiepileptic drug and/or rescue medication concomitantly administered to the human. 48B. The method of any one of the preceding embodiments, wherein the human suffers from drug-resistant PTE. 49B. The method of any one of the preceding embodiments, wherein the human suffers from debilitating drug-resistant PTE. 50B. The method of any one of embodiments 1B to 49B, wherein the pharmaceutical cannabinoid composition is administered daily. 51B. The method of any one of embodiments 1B to 49B, wherein the pharmaceutical cannabinoid composition is administered twice daily. 52B. The method of any one of embodiments 1B to 49B, wherein the pharmaceutical cannabinoid composition is administered at a dose between 100 mg and 1500 mg. 53B. The method of any one of embodiments 1B to 49B, wherein the pharmaceutical cannabinoid composition is administered at a dose of 200 mg daily or 100 mg twice daily. 30 ^sf-6205389 776772000640 54B. The method of any one of embodiments 1B to 49B, wherein the pharmaceutical cannabinoid composition is administered at a dose of 800 mg daily or 400 mg twice daily. 55B. The method of any one of embodiments 1B to 49B, wherein the pharmaceutical cannabinoid composition is administered at a dose of 1500 mg daily or 750 mg twice daily. 56B. A cannabinoid composition, comprising: cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC), collectively a major component of the cannabinoids present in the composition, wherein CBD, CBG and THC are provided as a combination of extracts or isolated from at least two cannabis cultivars, and wherein the weight ratio of CBD to CBG is 1 to between 0.016 and 0.15. 57B. The composition of embodiment 56B, wherein the weight ratio of CBD to THC is 1:0.003-0.03. 58B. The composition of embodiment 56B or 57B, wherein CBD, CBG and/or THC are provided as botanical drug substances (BDS). 59B. The composition of embodiment 58B, further comprising other cannabinoid and/or non-cannabinoid components that are present from the BDS. 60B. The composition of embodiment 58B, further comprising terpenes that are present from the BDS. 61B. The composition of any one of embodiments 58B to 60B, further comprising flavonoids that are present from the BDS. 62B. The composition of embodiment 56B or 57B, wherein CBD, CBG and THC are provided as a combination of cannabis extracts. 63B. The composition of embodiment 56B or 57B, wherein CBD, CBG and THC are provided as a combination of extracts from 2-4 cannabis cultivars. 64B. The composition of embodiment 56B or 57B, wherein CBD, CBG and THC are provided as a combination of extracts from genetically identical clones of 3 different cannabis cultivars. 31 ^sf-6205389 776772000640 65B. The composition of embodiment 64B, wherein the 3 different cannabis cultivars are a high CBD cultivar, a high CBG cultivar and a high THC cultivar. 66B. The composition of any one of embodiments 63B to 65B, wherein cannabis cultivars are Cannabis sativa cultivars. 67B. The composition of any one of embodiments 63B to 62B, further comprising other cannabinoid and/or non-cannabinoid components that are present from the extracts. 68B. The composition of any one of embodiments 63B to 67B, further comprising terpenes that are present from the extracts. 69B. The composition of any one of embodiments 63B to 68B, further comprising flavonoids that are present from the extracts. 70B. The composition of any one of embodiments 56B to 69B, further comprising additional CBD, CBG and/or THC provided in purified form. 71B. The composition of any one of embodiments 56B to 69B, further comprising additional CBD, CBG and/or THC isolates. 72B. The composition of embodiment 56B or 57B, wherein CBD, CBG and THC are provided as a combination of purified CBD, CBG and THC cannabis extracts. 73B. The composition of embodiment 56B or 57B, wherein CBD, CBG and THC are provided as a combination of CBD, CBG and THC isolates. 74B. The composition of embodiment 56B or 57B, wherein CBD, CBG and THC are provided as a combination of BDS and CBD, CBG and/or THC isolates. 75B. The composition of embodiment 56B or 57B, wherein CBD, CBG and THC are provided as a combination of BDS, and purified CBD, CBG and/or THC cannabis extracts. 76B. The composition of embodiment 56B or 57B, wherein CBD, CBG and THC are provided as a combination of BDS, and CBD, CBG and/or THC isolates. 77B. The composition of embodiment 56B or 57B, wherein CBD, CBG and THC are provided as BDS in combination with refined or synthetic CBD, CBG and/or THC. 32 ^sf-6205389 776772000640 78B. The composition of embodiment 56B or 57B, wherein CBD, CBG and THC are a combination of highly purified CBD, highly purified CBG and highly purified THC, wherein each of which are extracted from a cannabis plant and purified to the extent that other cannabinoids and a majority of non-cannabinoid components that are co-extracted with the cannabinoids have been removed. 79B. The composition of embodiment 78B, wherein the highly purified CBD is greater than or equal to 90% (w/w) pure; the highly purified CBG is greater than or equal to 90% (w/w) pure; and the highly purified THC is greater than or equal to 90% (w/w) pure. 80B. The composition of embodiment 56B or 57B, wherein CBD, CBG and THC are all naturally derived. 81B. The composition of embodiment 56B or 57B, wherein at least a portion of CBD, CBG and/or THC is naturally derived, and the other portion is synthetic and/or biosynthetic. 82B. The composition of any one of the preceding embodiments, wherein THC is present primarily in the form of (–)-delta-9-trans-tetrahydrocannabinol (Δ9-THC). 83B. The composition of any one of the preceding embodiments, further comprising at least one lipid excipient. 84B. The composition of embodiment 84B, wherein at least one lipid excipient is a winterized oil comprising long-chain mono-, di-, and triglycerides. 85B. The composition of any one of the preceding embodiments, further comprising docosahexaenoic acid (DHA), or eicosapentaenoic acid (EPA), or a combination thereof. 86B. The composition of any one of the preceding embodiments, wherein THC is present in less than 0.3% by weight of the total composition. 87B. The composition of any one of the preceding embodiments, wherein CBD is about 100 mg/ml, CBD is about 5 mg/ml, and THC is about 1 mg/ml. 88B. The composition of any one of the preceding embodiments, wherein the composition is formulated for oral delivery, and optionally wherein the composition further comprises one or more flavoring or masking agents. 33 ^sf-6205389 776772000640 89B. The composition of any one of the preceding embodiments, wherein the cannabinoid composition is formulated as a solution. 90B. The composition of embodiment 89B, wherein CBD is between about 50 mg/ml and 150 mg/ml. 91B. The composition of embodiment 90B, wherein CBD is between about 90 mg/ml and 110 mg/ml. 92B. The composition of any one of embodiments 89B to 91B, wherein CBG is between about 2.5 mg/ml and 7.5 mg/ml. 93B. The composition of any one of embodiments 89B to 92B, wherein THC is between about 0.5 mg/ml and 1.5 mg/ml. 94B. The composition of any one of embodiments 89B to 93B, wherein CBD is about 100 mg/ml, CBG is about 5 mg/ml, and THC is about 1 mg/ml. 95B. A method of treating post-traumatic epilepsy (PTE) in a human in need thereof, comprising: administering an initial dose of a cannabinoid composition comprising: cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC), collectively a major component of the cannabinoids present in the composition, wherein CBD, CBG and THC are provided as a combination of extracts or isolated from at least two cannabis cultivars, wherein the weight ratio of CBD to CBG is 1 to between 0.016 and 0.15. wherein the initial dose is between about 200 mg and 300 mg total daily dose, monitoring safety and effect on PTE, or the symptoms of PTE, experienced by the human in need thereof, and administering an increased dose of the cannabinoid composition, wherein the increased dose is up to a maximum total daily dose of about 1000 mg. 96B. A composition of any one of embodiments 56B to 94B for use in treating post- traumatic epilepsy (PTE). 97B. The composition of embodiment 96B for use in treating refractory PTE. 34 ^sf-6205389 776772000640 98B. The composition of embodiment 96B or 97B, wherein: the frequency of occurrence of seizures is decreased; or the severity of seizures is decreased; or anxiety is reduced; or mood is improved; or sleep quality is improved; or any combination of the foregoing. 99B. The composition of any one of embodiments 96B to 98B, wherein the method comprises administering the composition concomitantly with an antiepileptic drug and/or rescue medication. 100B. The composition of embodiment 99B, wherein the amount and/or frequency of the antiepileptic drug and/or rescue medication concomitantly administered is reduced. 101B. A composition of any one of embodiments 56B to 100B for use in treating post- traumatic epilepsy (PTE) in a patient population suffering from drug-resistant PTE. 102B. The composition of embodiment 101B, wherein the patient population suffers from debilitating drug-resistant PTE. EXAMPLES [0077] The presently disclosed subject matter will be better understood by reference to the following Examples, which are provided as exemplary of the invention, and not by way of limitation. Example 1A EXTRACTION AND ISOLATION OF CANNABINOIDS FROM THE PLANT [0078] Bulk plant material was isolated from dried cannabis flower. The bulk plant material was separated from the botanical starting material. The botanical starting materials were weighed and stored in an amber jar. The botanical starting material were added to an extraction vessel with solvent. The solvent was removed via vacuum distillation until only refined cannabis oil was present, with a low solvent concentration. The crude cannabis oil was then heated to for a suitable time to convert the THCA to THC to yield a refined 35 ^sf-6205389 776772000640 cannabis oil. The main cannabinoids, THCA, CBDA and CBGA were converted to the base molecule THC, CBD and CBG, respectively. Example 1B CHARACTERIZATION OF AN EXEMPLARY CANNABINOID COMPOSITION [0079] Exemplary cannabinoid compositions were produced according to Example 1A above, blended with botanical isolates to arrive at the amounts and ratios of CBD, CBG and THC as set forth in Table 1 below, and combined with an oil containing long chain mono, di, and triglycerides as the lipid vehicle. The following Table 1 provides the profile of exemplary drug product compositions, characterized based on cannabinoid content. The compositions were characterized using methods and techniques known in the art, including ultra-performance liquid chromatography (UPLC). Table 1.

Example 2 A RANDOMIZED CONTROLLED TRIAL INVESTIGATING THE SAFETY AND EFFICACY OF CANNABINOID COMPOSITION IN REFRACTORY POST- TRAUMATIC EPILEPSY (PTE) [0080] This study seeks to evaluate the safety and efficacy of Cannabinoid Composition A in the treatment of refractory PTE. The study drug is referred to herein as “Cannabinoid Composition A”, which is produced in accordance with the procedures set forth above in Examples 1A and 1B. For example, the study drug may include 100 mg/ml CBD, 5 mg/ml CBG, and 1 mg/ml Δ9-THC. The study drug is a botanically derived extract that contains less than 0.3% THC and other minor plant components in the lipid vehicle composed of mono-, di-, and triglycerides. The THC content is below the 0.3% THC allowable limit 36 ^sf-6205389 776772000640 established by the United States Department of Agriculture (USDA) 2018 Farm Bill for Hemp products. The study drug is formulated for oral use in a lipid vehicle. [0081] Study Objectives: [0082] Primary Objective(s): • To evaluate the safety and tolerability of Cannabinoid Composition A in adults with refractory PTE. • To evaluate the efficacy of Cannabinoid Composition A on seizure frequency in adults with refractory PTE. [0083] Secondary Objective(s): • To evaluate the efficacy of Cannabinoid Composition A on seizure severity. • To evaluate the efficacy of Cannabinoid Composition A on anxiety. • To evaluate the efficacy of Cannabinoid Composition A on mood. • To evaluate the efficacy of Cannabinoid Composition A on sleep quality. • To evaluate the efficacy of Cannabinoid Composition A on quality of life. • To evaluate the effect of Cannabinoid Composition A on the frequency of use and effectiveness of concomitant antiepileptic drugs and rescue medications. [0084] Study Design: This is a Phase 2 repeated-dose study to assess the safety and efficacy of Cannabinoid Composition A in adults with refractory PTE. The study will be divided into two consecutive parts: an open label dose finding phase (Part A) and a randomized placebo-controlled phase (Part B). An interim analysis will follow Part A, to assess safety and efficacy and better understand the dose response for Part B. Patients who are enrolled in Part A will not be eligible to participate in Part B. [0085] Duration of Subject Participation and Product Use: The total expected duration, including the screening and follow up periods for both Parts A and B is 18 weeks. The duration of study medication use will be 12 weeks. Fifty (50) enrolled participants; ten (10) in Part A and forty (40) in Part B. [0086] Dosage: 100 mg/mL, titrated based on safety and efficacy [0087] Dosing Schedule: Twice daily (q12h) for 12 consecutive weeks 37 ^sf-6205389 776772000640 [0088] Mode of administration: Oral [0089] Endpoints: [0090] Primary Endpoint(s): [0091] Safety will be assessed in terms of: • Adverse events (AEs) and serious AEs (SAEs) • Vital signs • Laboratory assessments [0092] Efficacy will be assessed in terms of: • Change from baseline to 12 weeks (post-treatment) in number of PTE-associated seizures [0093] Key Secondary Endpoint(s): • Number of patients considered treatment responders defined as those with a ≥ 50% reduction in PTE-associated seizure frequency. • Number of patients considered treatment responders defined as those with a ≥ 25%, ≥ 50%, ≥ 75% or 100% reduction in PTE-associated seizure frequency. • Number of patients experiencing a > 25% worsening, − 25 to + 25% no change, 25–50% improvement, 50–75% improvement or > 75% improvement in PTE-associated seizure frequency [0094] Secondary Endpoint(s): • Change in number of PTE-associated seizure-free days. • Seizure severity via the Seizure Severity Questionnaire (SSQ) • Emotional distress/depression via the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form • Sleep disturbance via the PROMIS Short Form • Performance of Social Roles and Activities via the PROMIS Short Form • Anxiety via the General Anxiety Disorder-7 (GAD-7) scale • Quality of life via QOLIE-31 38 ^sf-6205389 776772000640 • Use and effectiveness and of concomitant and frequency of rescue medications. • Compliance with study medication consumption recorded in daily diaries and confirmed by returned investigational product during the titration and maintenance periods Example 3 STUDY OF EFFECTS OF CANNABINOID FORMULATION IN POST- TRAUMATIC EPILEPSY (PTE) [0095] An individual diagnosed with post-traumatic epilepsy experienced an approximately 40% reduction in countable seizures after receiving a total daily dose of 10 mg/kg dose of CBD for approximately 2.5 months. After 2.5 months of CBD, the individual transitioned to a formulation that includes CBD, CBG, and THC as major components at a weight ratio of approximately 100:5:1 (CBD:CBG:THC) at a total daily dose of about 10 mg/kg (with respect to the amount of CBD). The formulation was administered twice daily. The individual surprisingly experienced an additional 30% reduction in countable seizures from the baseline (before CBD), increased activity level, improved sleep, and reduction in undesirable repetitive behaviors after approximately 1 month of daily 10 mg/kg doses of the formulation. The improvements observed after 1 month of administration of the formulation were sustained over 7 subsequent months of administration of the formulation. 39 ^sf-6205389

Claims

776772000640 CLAIMS What is claimed is: 1. A method of treating post-traumatic epilepsy (PTE) in a human in need thereof, comprising: administering a cannabinoid composition comprising: cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC), collectively a major component of the cannabinoids present in the composition, wherein CBD, CBG and THC are provided as a combination of extracts or isolated from at least two cannabis cultivars, and wherein the weight ratio of CBD to CBG is 1 to between 0.016 and 0.15. 2. The method of claim 1, wherein the initial dose is between about 200 mg and 300 mg total daily dose, wherein the method further comprises: monitoring safety and effect on PTE, or the symptoms of PTE, experienced by the human in need thereof, and administering an increased dose of the cannabinoid composition, wherein the increased dose is up to a maximum total daily dose of about 1000 mg. 3. The method of claim 1 or 2, wherein the weight ratio of CBD to THC is 1:0.003-0.03. 4. The method of any one of claims 1 to 3, wherein CBD, CBG and/or THC are provided as botanical drug substances (BDS). 5. The method of claim 4, wherein the cannabinoid composition further comprises other cannabinoid and/or non-cannabinoid components that are present from the BDS. 6. The method of any one of claims 1 to 3, wherein CBD, CBG and THC are provided as a combination of cannabis extracts. 7. The method of any one of claims 1 to 3, wherein CBD, CBG and THC are provided as a combination of extracts from 2-4 cannabis cultivars. 40 ^sf-6205389 776772000640 8. The method of any one of claims 1 to 3, wherein CBD, CBG and THC are provided as a combination of extracts from genetically identical clones of 3 different cannabis cultivars. 9. The method of claim 8, wherein the 3 different cannabis cultivars are a high CBD cultivar, a high CBG cultivar and a high THC cultivar. 10. The method of any one of the preceding claims, wherein CBD, CBG and THC are collectively greater than 50% by weight of the cannabinoids present in the composition. 11. The method of any one of the preceding claims, wherein the composition is formulated for oral delivery. 12. The method of any one of the preceding claims, wherein the cannabinoid composition is formulated as a solution. 13. The method of claim 12, wherein CBD is between about 90 mg/ml and 110 mg/ml. 14. The method of claim 12 or 13, wherein CBG is between about 2.5 mg/ml and 7.5 mg/ml. 15. The method of any one of claims 12 to 14, wherein THC is between about 0.5 mg/ml and 1.5 mg/ml. 16. The method of any one of claims 12 to 15, wherein CBD is about 100 mg/ml, CBG is about 5 mg/ml, and THC is about 1 mg/ml. 17. The method of any one of the preceding claims, wherein the PTE is refractory PTE. 18. The method of any one of the preceding claims, wherein the treatment: decreases the frequency of occurrence of seizures in the human; or decreases the severity of seizures in the human; or reduces anxiety in the human; or improves mood in the human; or improves sleep quality in the human, or any combination of the foregoing. 41 ^sf-6205389 776772000640 19. The method of any one of the preceding claims, wherein the human concomitantly takes an antiepileptic drug and/or rescue medication. 20. The method of claim 19, wherein the treatment reduces the amount and/or frequency of the antiepileptic drug and/or rescue medication concomitantly administered to the human. 21. The method of any one of the preceding claims, wherein the human suffers from drug-resistant PTE. 22. The method of any one of the preceding claims, wherein the human suffers from debilitating drug-resistant PTE. 23. The method of any one of claims 1 to 22, wherein the cannabinoid composition is administered at a dose between 100 mg and 1500 mg. 24. The method of any one of claims 1 to 23, wherein the cannabinoid composition is administered at a dose of: (i) 200 mg daily or 100 mg twice daily; or (ii) 800 mg daily or 400 mg twice daily; or (iii) 1500 mg daily or 750 mg twice daily. 25. A cannabinoid composition, comprising: cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC), collectively a major component of the cannabinoids present in the composition, wherein CBD, CBG and THC are provided as a combination of extracts or isolated from at least two cannabis cultivars, and wherein the weight ratio of CBD to CBG is 1 to between 0.016 and 0.15. 26. The composition of claim 25, wherein the weight ratio of CBD to THC is 1:0.003- 0.03. 27. The composition of claim 25 or 26, wherein CBD, CBG and/or THC are provided as botanical drug substances (BDS). 28. The composition of claim 27, further comprising other cannabinoid and/or non- cannabinoid components that are present from the BDS. 42 ^sf-6205389 776772000640 29. The composition of claim 27 or 28, wherein CBD, CBG and THC are provided as a combination of cannabis extracts. 30. The composition of any one of claims 25 to 29, wherein CBD is about 100 mg/ml, CBG is about 5 mg/ml, and THC is about 1 mg/ml. 31. A composition of any one of claims 25 to 30, for use in treating post-traumatic epilepsy (PTE). 43 ^sf-6205389